Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $653K | $295K | — | — | — | — | — | — | — | — |
| Revenue growth | — | -54.8% | — | — | — | — | — | — | — | — |
| Operating income | -$81.0M | -$84.3M | -$26.9M | -$45.4M | -$19.3M | -$27.0M | -$34.6M | -$29.2M | -$42.0M | -$26.6M |
| Operating margin | -12406.1% | -28585.1% | — | — | — | — | — | — | — | — |
| Net income | -$82.3M | -$84.6M | -$27.2M | -$44.6M | -$19.2M | -$28.3M | -$35.7M | -$29.5M | -$41.8M | -$26.3M |
| Net margin | -12597.2% | -28670.5% | — | — | — | — | — | — | — | — |
| EPS (diluted) | -$2.56 | -$321.81 | -$17.58 | -$3.25 | -$41.03 | -$7.47 | -$3.09 | -$1.91 | -$19.50 | -$6.33 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$61.7M | -$20.3M | -$23.6M | -$41.2M | -$19.0M | -$26.0M | -$31.1M | -$27.4M | -$33.0M | -$26.8M |
| Capital expenditures | $2.59M | $4.00K | $36.0K | $397K | $50.0K | $135K | $562K | $170K | $435K | $0.00 |
| Free cash flow | -$64.3M | -$20.3M | -$23.7M | -$41.6M | -$19.1M | -$26.1M | -$31.6M | -$27.5M | -$33.5M | -$26.8M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $43.9M | $17.6M | $73.3M | $62.5M | $18.8M | $51.8M | $31.2M | $39.2M | $30.3M | $7.71M |
| Total assets | $123M | $19.8M | $84.1M | $75.0M | $22.9M | $73.2M | $46.1M | $51.6M | $41.5M | $16.9M |
| Total liabilities | $14.3M | $4.83M | $11.0M | $15.1M | $4.95M | $37.1M | $28.0M | $24.8M | $22.4M | $10.3M |
| Long-term debt | — | $599K | $383K | $168K | $61.0K | $15.1M | $10.4M | $6.26M | $0.00 | — |
| Shareholders' equity | $108M | -$131M | $71.0M | -$50.4M | -$68.8M | $36.1M | $18.1M | $26.8M | $19.1M | $6.67M |
| Retained earnings | -$250M | -$137M | -$164M | -$209M | -$71.8M | -$100M | -$136M | -$165M | -$207M | -$233M |
| Shares (wtd avg diluted) | 35.6M | 246K | 13.4M | 18.3M | 468K | 3.79M | 11.5M | 15.4M | 2.15M | 4.15M |
Every figure is extracted from Tempest Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.